Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 9,963 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MATCH Clear all
Terminated Phase 2 Interventional Results available

Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism

NCT00862563
View directory record Official record
Conditions
Alcoholism, Alcohol Dependence, Alcohol Abuse
Interventions
Topiramate, Zonisamide, Levetiracetam, Sugar Pill
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Not applicable Interventional

Promoting Responsible Drinking: An Internet-based, Interactive Computer Tailored Intervention

NCT02126163
View directory record Official record
Conditions
Regular Heavy AOD Use, Excessive Drinking
Interventions
Treatment Group
Behavioral
Lead sponsor
Pro-Change Behavior Systems
Other
Eligibility
21 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
South Kingstown, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 21, 2026, 2:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Brain Antioxidants During Oxidative Stress

NCT01713816
View directory record Official record
Conditions
Oxidative Stress, Alzheimer's Disease, Aging
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years to 89 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 2 Interventional

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

NCT00350181
View directory record Official record
Conditions
Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
Interventions
Sirolimus, MMF, BCNU, VP-16, CY, FTBI, BU
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Not applicable Interventional

The Effect of Resistance to Participant-Supported Reaching on Workspace of the Hand in Severe Chronic Stroke

NCT01548781
View directory record Official record
Conditions
Stroke
Interventions
Impairment-based robotic intervention for reaching function
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Not applicable Interventional Results available

Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients

NCT01784419
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ivacaftor, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 21, 2026, 2:03 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

NCT03893565
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GSK2831781 - Double Blind Phase, Placebo, GSK2831781 - Open Label phase
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Northridge, California • Rialto, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 21, 2026, 2:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys

NCT06230367
View directory record Official record
Conditions
HIV Infections
Interventions
Sexual health advocacy for guys, Healthy lifestyle control
Behavioral
Lead sponsor
Center for Innovative Public Health Research
Other
Eligibility
13 Years to 22 Years · Male only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
San Clemente, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

NCT03042611
View directory record Official record
Conditions
Gastric Cancer, Gastric Adenocarcinoma
Interventions
Rivoceranib, Placebo
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Rogers, Arkansas • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

NCT06031844
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
DFV890, DFV890 Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Northridge, California • Boca Raton, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

NCT02540993
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
176
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 21, 2026, 2:03 PM EDT
Recruiting Not applicable Interventional

Comparing Structured Retrieval Practice and Reading-Based Education for Dementia Caregivers

NCT07413406
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Caregiver Stress
Interventions
Structured Retrieval Practice, Reading-Based Education
Behavioral
Lead sponsor
Virginia Wesleyan University
Other
Eligibility
50 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 3 Interventional

A 1-Year Study in Multiple Clinics Testing Rebamipide Eye Drops for Dry Eye Compared With a Placebo

NCT00201981
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Rebamipide 1%, Rebamipide 2%, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Glendale, Arizona • Peoria, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Not applicable Interventional

Magnamosis First-in-human Study of Feasibility and Safety

NCT02043392
View directory record Official record
Conditions
Intestinal Anastomosis Complication
Interventions
Magnamosis
Device
Lead sponsor
Michael Harrison
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

NCT03332732
View directory record Official record
Conditions
Bacterial Infections
Interventions
VNRX-5133, VNRX-5022, Metronidazole, Placebo
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Smoking Cessation Via Text Messaging: Feasibility Testing of Stop My Smoking USA

NCT01516632
View directory record Official record
Conditions
Smoking Cessation
Interventions
SMS USA
Behavioral
Lead sponsor
Center for Innovative Public Health Research
Other
Eligibility
18 Years to 25 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 1Phase 2 Interventional

Sirtuin-NAD Activator in Alzheimer's Disease

NCT05040321
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Dementia
Interventions
MIB-626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

UW Quitting Using Intensive Treatment Study (QUITS)

NCT03176784
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Varenicline, Nicotine patch, Placebo Patch, Placebo Pill
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Wellness Interventions After Transplant Study

NCT00367809
View directory record Official record
Conditions
Organ Transplant
Interventions
Mindfulness-Based Stress Reduction (MSBR), Health Education (HE), Delayed Intervention
Behavioral
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Oct 21, 2026, 2:03 PM EDT
Completed No phase listed Observational

Blood Volume Analysis and Renal Outcomes in Hemodialysis

NCT02717533
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Actual Impaired Fluid Volume, Kidney Failure
Interventions
dry weight adjustment
Other
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 21, 2026, 2:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)

NCT00879333
View directory record Official record
Conditions
Advanced Gastric Cancer
Interventions
Everolimus, Everolimus placebo, Best Supportive Care (BSC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Fayetteville, Arkansas • Redlands, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 21, 2026, 2:03 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT07122193
View directory record Official record
Conditions
Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents, incobotulinumtoxinA, Botulinum Toxins, Type A
Interventions
NT 201, NT 201 Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 2:03 PM EDT
Terminated Phase 3 Interventional Results available

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

NCT02715804
View directory record Official record
Conditions
Pancreatic Ductal Carcinoma
Interventions
Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel, Gemcitabine
Other · Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 21, 2026, 2:03 PM EDT